Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T versus abiraterone acetate or enzalutamide in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer
CTR20221644Phase 3Active
- Sponsor
- Shanghai Danrui Biopharmaceutical Technology
- Start
- Jun 2023
- Modality
- Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sipuleucel-T, abiraterone, enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Shanghai Danrui Biopharmaceutical Technology. Started Jun 2023; status: active.
02
Drugs
sipuleucel-Tabirateroneenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20221644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221644.